Homologous and heterologous antibody responses to a one-year booster dose of an MF59®: Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 7, 2012, Pages 921-928

  Vesikari, Timo ^a   Forstén, Aino ^a   Borkowski, Astrid ^b   Gaitatzis, Nikolaos ^b   Banzhoff, Angelika ^b   Clemens, Ralf ^b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b GSK Marburg Vaccines and Diagnostics   (Germany)

Author keywords

Adjuvant; Antibody persistence; Avian influenza; Cross clade immunity; H5N1; Heterologous immunity; Influenza vaccine; MF59; Pandemic; Pediatric

Indexed keywords

FLUNOV; INFLUENZA VACCINE; MIFAMURTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHILD; CHILL; CONTROLLED STUDY; CROSS REACTION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FOREARM FRACTURE; GASTROENTERITIS; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IRRITABILITY; MALAISE; MYALGIA; NAUSEA; NORMAL HUMAN; OTITIS MEDIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; SWELLING; SYSTEMIC DISEASE; TONSILLITIS; TREATMENT DURATION; VOMITING;

EID: 84864108343     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20248     Document Type: Article

References (25)

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 29 November 2011; http://www.who.int/ influenza/human-animal-interface/H5N1-cumulative-table-archives/en/index.html.
2. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:4384; PMID:19197383; http://dx.doi.org/10.1371/journal.pone.0004384.
3. Leroux-Roels I, Van der Wielen M, Kafeja F, Vandermeulen C, Lazarus R, Snape MD, et al. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine 2009; 27:6918-25; PMID:19761837; http://dx.doi.org/10.1016/j.vaccine.2009.08.110.
4. Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 2006; 103:2845-50; PMID:16473931; http://dx.doi.org/10.1073/pnas.0511120103.
5. Webster RG, Govorkova EA. H5N1 influenza - continuing evolution and spread. N Engl J Med 2006; 355:2174-7; PMID:17124014; http://dx.doi. org/10.1056/NEJMp068205.
6. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106:7962-7; PMID:19416838; http://dx.doi.org/10.1073/pnas. 0903181106.
7. De Donato S, Granoff D, Minutello M, Lecchi G, Faccini M, Agnello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17:3094-101; PMID:10462245; http://dx.doi.org/10.1016/ S0264-410X(99)00138-3.
8. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135-40; PMID:11599686; http://dx.doi.org/10.1023/A:1017919305501.
9. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699-710; PMID:17931151; http://dx.doi.org/10.1586/14760584.6.5.699.
10. Puig Barberà J, González Vidal D. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev Vaccines 2007; 6:659-65; PMID:17931147; http://dx.doi.org/10.1586/14760584.6.5.659.
11. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49:177-84; PMID:12679609; http://dx.doi.org/10.1159/000069172.
12. de Roux A, Marx A, Burkhardt O, Schweiger B, Borkowski A, Banzhoff A, et al. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. Vaccine 2006; 24:1537-42; PMID:16288937; http://dx.doi.org/10.1016/j.vaccine.2005.10.007.
13. Iorio AM, Francisci D, Camilloni B, Stagni G, De Martino M, Toneatto D, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003; 21:3629-37; PMID:12922092; http://dx.doi.org/10.1016/S0264- 410X(03)00408-0.
14. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx.doi.org/10.1097/INF.0b013e31819d6394.
15. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010; 126:762-70; PMID:20819892; http://dx.doi.org/10.1542/peds.2009-628.
16. Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631-3; PMID:18843132; http://dx.doi.org/10.1056/ NEJMc0805274.
17. th Annual Meeting of the European Society for Paediatric Infectious Diseases. Nice, France. 4-8 May 2010.
18. th Annual Meeting of the European Society for Paediatric Infectious Diseases. Nice, France. 4-8 May 2010.
19. Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, et al. Immunogenicity, Safety and Reactogenicity of a Mammalian Cell-Culture-Derived Influenza Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age. Pediatr Infect Dis J 2012; PMID:22301476; http://dx.doi.org/10.1097/INF. 0b013e31824bb179.
20. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009; 27:6291-5; PMID:19840662; http://dx.doi.org/10.1016/j.vaccine.2009.02.004.
21. Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011; 7:539-48; PMID:21422814; http://dx.doi.org/10.4161/hv.7.5.14821.
22. Tsai TF, Crucitti A, Nacci P, Nicolay U, Cioppa GD, Ferguson J, et al. Explorations of clinical trials and pharmacovigilance databases of MF59((R))-adjuvanted influenza vaccines for associated cases of narcolepsy. J Infect Dis.
23. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004; 4:499-509; PMID:15288823; http://dx.doi.org/10.1016/S1473- 3099(04)01105-3.
24. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43; PMID:11425416; http://dx.doi.org/10.1016/S0140-6736(00)05066-2.
25. Schild GC, Pereira MS, Chakraverty P. Single-radialhemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975; 52:43-50; PMID:1082381.